- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01683136
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder
This is an open study.approximately 20 patients diagnosed with Borderline Personality Disorder (in case patient is under drug treatment, treatment should be stable within the prior 4 weeks before study entry).Starting from the third day, subjects would undergo rTMS (repetitive Transcranial Magnetic Stimulation) for five days a week, for four weeks, and will be clinically evaluated in order to monitor for improvement.
The investigators anticipate a significant reduction in symptoms severity at the end of the treatment compared to study entry.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The symptoms of borderline personality disorder can be treated, but there is no known cure.
Several recent studies have shown that patients suffering from borderline personality disorder (BPD) express a significant hypoactivity and smaller gray matter concentration in the anterior cingulate cortex (ACC), compared to healthy controls.
In this current study we are attempting to find a better solution for the treatment of Borderline Personality Disorder using deep Transcranial magnetic stimulation (dTMS) technology.
The HBDL coil is intended to induce activation of prefrontal and orbitofrontal brain structures, including the ACC, in order to induce long term potentiation in this brain region.
The protocol includes bilateral stimulation to the SMA at 110% of the motor threshold of the Abductor Policies Brevis and at a frequency of 10 Hz. each session is comprised of four cycles of 3 seconds of stimulation and a 20 seconds recess(Total number of pulses: 1200).approximately 20 patients diagnosed with Borderline Personality Disorder will participate. subjects would undergo rTMS sessions for five days a week, for four weeks, using the HBDL dTMS coil. this coil is capable of producing a magnetic field in deeper parts of the cerebral cortex, and for that reason we believe that it can produce better clinical outcomes then superficial TMS coils used in earlier studies.
The goal of this study is to determine the safety and efficacy of transcranial magnetic stimulation (TMS) in treating patients suffering from borderline personality disorder.
Our main objective is to observe a reduction in the severity of the symptoms post treatment in comparison to pre treatment, using the zan-bpd as the main outcome measure. Additional objective is to observe normalizaition of borderline's empathic tendencies: on one hand, we expect their affective empathy to be compromised post treatment in comparison to pre treatment. on the other hand, we expect heir cognitive empathy to be increased post treatment in comparison to pre treatment.
Note that on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.
the 20 day of treatments will be started from the third day.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hilik Levkovitz, prof.
- Phone Number: 972-9-7478568
- Email: ylevk@clalit.org.il
Study Contact Backup
- Name: Hila Gvirts, MA
- Phone Number: 972-9-7478644
- Email: hilagv@clalit.org.il
Study Locations
-
-
-
Hod Hasharon,, Israel
- Shalvata Mental health Center
-
Contact:
- Hillik Levkovitz, Prof
- Phone Number: 972-9-7478568
- Email: ylevk@clalit.org.il
-
Contact:
- Hagai Harari, MD
- Phone Number: 972-9-7478500
- Email: rreh@clalit.org.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and woman between the ages of 18-60
- Diagnosed as suffering from Borderline Personality Disorder according to the DSM IV, as determined by a senior psychiatrist on the basis of the Structured Clinical Interview for DSM-IV Axis I
- pharmocological treatment stays constant for the duration of the study
- Gave informed consent for participation in the study
- Not pregnant
Exclusion Criteria:
- Electroconvulsive therapy (ECT) less than 9 months prior to screening.
- suicide risk (assessed by the patient's doctor)
- Suffer from active AXIS I disorder (according to the DSM IV)during the 3 months before study entry(besides: eating disorder, phobia and somatoform disorder)
- History of seizure or heat convulsion.
- History of epilepsy or seizure in first degree relatives.
- History of head injury.
- History of any metal in the head (outside the mouth).
- Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.
- History of frequent or severe headaches.
- History of migraine.
- History of hearing loss.
- Pregnancy or not using a reliable method of birth control.
- Inadequate communication with the patient.
- Under custodial care.
- Participation in current clinical study or
- A significant physical illness which is not balanced.
- Cerebral Palsy, history of encephalitis or other structural brain damage.
- Pseudotumor cerebri
- neurological deficit
- Patients using high dosage of antipsychotic medicine :
more than 7.5 mg Haldol, 10 mg Olanzapine, 4 mg Risperdal, 400 mg SEROQUEL, 120 mg Geodon, 100 mg Clopixol, 12 mg Perphenan.
Patients taking Clozapine will not be recruited to the present study In case of taking other antipsychotic medicine besides those listed above, the principal investigator will decide whether patients are eligible for recruitment .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deep TMS treatment
|
on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities. From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks |
Sham Comparator: inactive stimulation
|
on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities. From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in ZAN-BPD
Time Frame: every 2 weeks, up to 4 weeks.
|
every 2 weeks, up to 4 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hagai Harari, MD, Shalvata Mental health Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHA-09-11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University of EdinburghRecruitingEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Silvia Elisa Hurtado SantiagoCompletedPersonality Disorder, BorderlineSpain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Universitat Jaume IHospital de la RiberaNot yet recruitingBorderline Personality Disorder (BPD)Spain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
-
Rutgers, The State University of New JerseyActive, not recruitingBorderline Personality Disorder in AdolescenceUnited States
Clinical Trials on HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)
-
Shalvata Mental Health CenterUnknownObsessive Compulsive Disorder | Tourette's SyndromeIsrael
-
Centre for Addiction and Mental HealthBrainswayCompleted
-
Shanghai Mental Health CenterRecruitingTreatment Resistant Schizophrenia Based on the DTMSChina
-
Hadassah Medical OrganizationCompletedPost Traumatic Stress DisorderIsrael
-
Charite University, Berlin, GermanyBrainswayCompletedMultiple SclerosisGermany
-
Shenzhen Kangning HospitalThe National Natural Science Foundation of China (NSFC)Not yet recruitingAnxiety State | Anxiety Disorder
-
Douglas Mental Health University InstituteBrainswayCompletedMajor Depressive DisorderCanada
-
The New York Memory ServicesCompletedDementia | Aphasia | Alzheimer's DiseaseUnited States
-
University of BrasiliaCompletedObsessive Compulsive DisorderBrazil
-
University of Sao PauloBrainswayCompleted